Study of gene network could lead to new treatment for different neurological disorders

A mutated gene found in people with intellectual disabilities that could be targeted for treatment has been identified by an international team including University of Queensland researchers.

The gene, USP9X, regulates a network of genes underlying Intellectual Disability (ID) and Autism Spectrum Disorder (ASD).

UQ School of Biomedical Sciences Associate Professor Michael Piper said focussing on the network, rather than individual genes, could lead to therapy developments for a range of neurological disorders.

Treating ID and ASD one gene at a time is not feasible, as more than 1000 genes have been implicated in the conditions.

Research is switching to identifying networks in which multiple genes function in common pathways, such as USP9X.

USP9X regulates a family of proteins that control how nerves communicate and share information.

By targeting this network, there is a possibility that treatments could be developed that will help a wide range of patients.

Associate Professor Michael Piper, UQ School of Biomedical Sciences

Mice lacking the USP9X gene were used to study the function of this factor, as well as its interacting partners.

Mutations in USP9X have also been implicated in Parkinson's and Alzheimer's diseases.

The research showed a critical two-week period following birth where development of USP9X is crucial to normal brain function.

"This represents a window of opportunity for therapeutical intervention," Dr Piper said.

"It is possible that this model will help test interventions in mice as a step towards developing new therapeutic approaches for patients."

Source:
Journal reference:

Yoon, S. et al. (2019) Usp9X Controls Ankyrin-Repeat Domain Protein Homeostasis during Dendritic Spine Development. Neuron. doi.org/10.1016/j.neuron.2019.11.003

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows how a single defective BRCA1 gene accelerates cancer development